DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award

The FY26 Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award (OCCTA-ECI) program, offered by the Defense Health Agency, aims to foster early-career investigators in ovarian cancer clinical trial research. This funding opportunity, totaling $4.2M for approximately three awards of up to $1.4M each over four years, supports translational research and small-scale, early-phase clinical trials. Eligibility requires Early-Career Investigators to be within 12 years of their last postdoctoral research position or clinical fellowship, commit at least 25% effort, and be guided by an experienced Designated Mentor. The two-step application process involves a pre-application (Letter of Intent) due September 15, 2026, and a full application due October 1, 2026. Submissions require detailed project narratives, career development plans, and statements of commitment to the OCCTA. Applications undergo a two-tier review process, including peer and programmatic review, focusing on the investigator's potential, mentorship quality, study design, and clinical impact, with emphasis on military health relevance.

The FY26 Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award (OCCTA-ECI) program, offered by the Defense Health Agency, aims to foster early-career investigators in ovarian cancer clinical trial research. This funding opportunity, totaling $4.2 million for approximately three awards of up to $1.4 million each over four years, supports translational and small-scale, early-phase clinical trials. Applicants, who must be within 12 years of their last postdoctoral position, require a Designated Mentor with a strong mentoring record and an active clinical trial. The application process is two-step, involving a pre-application (Letter of Intent) due September 15, 2026, and a full application due October 1, 2026. Key application components include a Project Narrative, Career Development and Sustainment Plan, and letters from mentors, emphasizing the ECI’s commitment, the mentor’s expertise, and the project’s impact on ovarian cancer and military health. Applications undergo a two-tier review process (peer and programmatic) with a focus on scientific merit and programmatic relevance.

The FY26 Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award, offered by the Defense Health Agency's Ovarian Cancer Research Program, seeks to fund approximately three clinical trial research applications with a total cost cap of $1.4 million per award over a maximum of four years. The program supports early-career investigators (ECIs) within 12 years of their last postdoctoral or clinical fellowship, who must commit at least 25% effort to the award. Key requirements include preliminary data, a Designated Mentor with significant clinical trial and mentoring experience, and a focus on small-scale, early-phase ovarian cancer clinical trials. The application process involves a pre-application (Letter of Intent) and a full application, with deadlines of September 15, 2026, and October 1, 2026, respectively. Extramural organizations submit through Grants.gov, while intramural Department of War organizations use eBRAP. Applications are evaluated through a two-tier review process (peer and programmatic) based on the ECI's potential, career development plan, mentor qualifications, clinical impact, and study design. The program aims to foster the next generation of ovarian cancer clinical trialists.